| Dr Lucas Paul Neff, MD | |
|
Travis Afb, 60 Msgs/sgcqg, David Grant Medical Center, 101 Bodin Circle, Bldg 777, Apo, AA 94535 | |
| (707) 423-5179 | |
| Not Available |
| Full Name | Dr Lucas Paul Neff |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 18 Years |
| Location | Travis Afb, 60 Msgs/sgcqg, Apo, Armed Forces Americas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578743076 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | A121906 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wake Forest University Health Sciences | 4486564952 | 1987 |
News Archive
The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.
Being overweight and resistant to insulin constitute a greater risk for fatty liver than was previously thought, according to a study from Linköping University in Sweden that is now being published in the journal Annals of Medicine.
Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.
› Verified 2 days ago
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.
Being overweight and resistant to insulin constitute a greater risk for fatty liver than was previously thought, according to a study from Linköping University in Sweden that is now being published in the journal Annals of Medicine.
Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucas Paul Neff, MD Travis Afb 60 Msgs/sgcqg, 101 Bodin Circle, Bldg 777, Apo, AA 94535 Ph: (707) 423-5179 | Dr Lucas Paul Neff, MD Travis Afb, 60 Msgs/sgcqg, David Grant Medical Center, 101 Bodin Circle, Bldg 777, Apo, AA 94535 Ph: (707) 423-5179 |
News Archive
The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.
Being overweight and resistant to insulin constitute a greater risk for fatty liver than was previously thought, according to a study from Linköping University in Sweden that is now being published in the journal Annals of Medicine.
Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.
› Verified 2 days ago
Dr. Christopher Wesley Mangieri, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 300 E Hospital Rd., Fort Gordon, Ga 30905, Eisenhower Army Medical Center, Dept. General Surgery, Apo, AA 30905 Phone: 706-305-7232 | |
Dr. Mark A. Coomes, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 23rd Medical Group/sghc, 3278 Mitchell Blvd, Apo, AA 31699 Phone: 229-257-1459 |